GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-05-09| M&A

Finland’s Orion Strikes for Jemincare’s Non-Opioid Painkiller, Paying $15 Million Upfront

by Joy Lin
Share To

Finnish pharma Orion Corporation is laying hands on China-based Jemincare’s non-opioid drug candidate, a treatment for pain that blocks the NaV 1.8 pathway. 

Under the new agreement between the two pharmas, Orion will pay Jemincare EUR 15 million ($15.77 million) for the investigational drug, as well as milestone payments that could be “significant” in scale. Jemincare will also receive tiered royalties between 8% and 15% on future product sales.

Orion gets global development and marketing rights, excluding the Greater China area (mainland China, Hong Kong, Macau, and Taiwan) for the NaV 1.8 blocker. The company will also be responsible for developing, producing and selling costs in its target markets. 

Additionally, the company will receive ownership to certain patent applications related to the compound within its territory. 

Related article: Compensating for OxyContin: The Harm from Pharma

 

A Potent and Selective NaV 1.8 Blocker

 

“Pain is one of the most frequently reported reasons for a patient to visit a health care provider and it generates a significant societal burden in terms of health care utilization and lost productivity,” said Outi Varaala, MD, PhD, Senior Vice President of Research and Development at Orion. 

Given the need for non-addictive treatment options that are both effective and safe, the NaV 1.8 channel may be a promising target for novel pain treatments, said Vaarala. 

NaV 1.8 is a subtype of sodium channel modulating the excitability of pain fibers. It has been shown to be a promising target in preclinical studies. However, no drugs selectively targeting NaV 1.8 have made it to the market.

That’s where Jemincare’s candidate, JMKX000623, comes in. A potent and selective blocker of the pain transmission pathway, the drug received IND approval in China this March. 

The success of the drug could be a turning point for Orion, after the pharma cut its staff and announced a change in their R&D strategy in March. Together with Jemincare, the companies aim to take the painkiller through clinical trials later this year.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
IPO
China’s Ascentage Snatches First Biotech IPO Price of 2025, Raking in $126M
2025-01-24
Looking at the Bigger Picture: 5 Key Takeaways from JPM 2025
2025-01-23
Trump’s Move to Ditch the WHO Again: Day 1 Sees a Slew of Executive Orders Signed Off
2025-01-21
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top